{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-004073","form_type":"8-K","ticker":"MXCT","cik":"0001287098","company_name":"MAXCYTE, INC.","filed_at":"2022-03-22T23:59:59+00:00","discovered_at":"2026-05-14T18:04:05.787337+00:00","generated_at":"2026-06-26T20:39:12.277222+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"MaxCyte Q4 revenue record $10.2M (+19%), FY2021 $33.9M (+30%); guides 2022 core growth 22-25%","bullets":["Record Q4 revenue $10.2M (+19% YoY); FY revenue $33.9M (+30% YoY).","Core cell therapy revenue grew 43% in Q4, drug discovery 32%; SPL program revenue $2.5M FY.","Net loss $4.9M Q4, $19.1M FY; EBITDA loss $4.5M Q4, $17.4M FY; stock-based comp $2.4M Q4, $8.0M FY.","2022 guidance: core revenue growth 22-25% YoY, SPL program revenue ~$4M.","SPL partners now 16 covering >95 programs; potential pre-commercial milestones >$1.25B."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-004073","json":"https://secwatch.observer/filing/0001558370-22-004073.json","markdown":"https://secwatch.observer/filing/0001558370-22-004073.md","text":"https://secwatch.observer/filing/0001558370-22-004073.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1287098/000155837022004073/0001558370-22-004073-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1287098/000155837022004073/mxct-20220322x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T20:39:12.277222+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}